單國(guó)洪先生于2017年9月18日起出任武田中國(guó)總裁，常駐上海，全面負(fù)責(zé)武田中國(guó)（包括香港、澳門地區(qū)）的整體戰(zhàn)略及業(yè)務(wù)增長(zhǎng)，同時(shí)也是武田成長(zhǎng)與新興市場(chǎng)管理層委員。在他的領(lǐng)導(dǎo)下，武田中國(guó)成功實(shí)現(xiàn)了戰(zhàn)略轉(zhuǎn)型，近年來(lái)業(yè)務(wù)高速發(fā)展，中國(guó)市場(chǎng)已成為武田全球最重要的戰(zhàn)略市場(chǎng)之一。 單國(guó)洪先生擁有逾二十年以上行業(yè)管理經(jīng)驗(yàn)，對(duì)中國(guó)的醫(yī)療及制藥行業(yè)有著獨(dú)到的洞察和深刻的認(rèn)知。在加入武田之前，他曾出任輝瑞創(chuàng)新集團(tuán)中國(guó)區(qū)總經(jīng)理、阿斯利康中國(guó)區(qū)副總裁等跨國(guó)藥企高級(jí)管理職位；同時(shí)還曾擔(dān)任輝瑞全球腫瘤委員會(huì)，阿斯利康全球呼吸領(lǐng)域品牌委員會(huì)成員等職務(wù)。憑借其豐富的國(guó)際化管理經(jīng)驗(yàn)以及深刻的行業(yè)洞察力，他曾成功地領(lǐng)導(dǎo)了腫瘤、免疫、罕見(jiàn)病及疫苗等多個(gè)疾病領(lǐng)域的創(chuàng)新產(chǎn)品在中國(guó)大陸、香港及澳門地區(qū)的獲批與上市，使這些創(chuàng)新藥品更早惠及中國(guó)患者。 作為一名醫(yī)療行業(yè)資深專業(yè)人士，單國(guó)洪先生活躍于各項(xiàng)社會(huì)事務(wù)，并擔(dān)任多個(gè)社會(huì)職務(wù)。他是中國(guó)癌癥基金會(huì)和中國(guó)醫(yī)藥生物技術(shù)協(xié)會(huì)的常務(wù)理事，中國(guó)外商投資企業(yè)協(xié)會(huì)藥品研制和開(kāi)發(fā)行業(yè)委員會(huì)（RDPAC）執(zhí)行委員會(huì)委員，也是復(fù)旦大學(xué)管理學(xué)院的校友導(dǎo)師，并擁有美國(guó)華盛頓大學(xué)和復(fù)旦大學(xué)高級(jí)工商管理碩士（EMBA）學(xué)位。 ? ?Sean Shan has been appointed as President of Takeda China since 18 September 2017, taking full responsibilities for Takeda’s overall strategy and business development in China, including Hong Kong and Macao. In addition to his role as China head, he also sits on the Leadership Committee of Growth & Emerging Markets of Takeda, representing China market. Under his leadership Takeda China has accelerated its strategic transformation with great success recently. The businesses keep a fast pace with strong growth across broad therapeutic areas. China now is seen one of the most important strategic markets at Takeda worldwide. ? ?Bringing his over 20 years’ experiences in pharmaceutical industry in China, Sean is a seasoned executive with versatile functional expertise in marketing and sales, business development. Before joining Takeda, he took several roles as senior executive in the leading MNCs, such as General Manager of Innovation Healthcare of Pfizer China, Vice President of Astra Zeneca China etc. Apart from his country leadership role, he also held global key positions as the member of Global Oncology Council of Pfizer, Global Respiratory Brand Council of Astra Zeneca. Combining his international leadership experience and in-depth functional expertise in pharmaceutical industry, he has been leading several new drugs approval and launch across mainland China, Hong Kong and Macao, with specific to oncology, immunology, rare disease and vaccine. More Chinese patients are benefitting now from these innovative medicines. ? ?As a senior healthcare professional Sean has been proactively taking social responsibilities and roles. He is now a standing member of the board of China Cancer Foundation and China Medical and Biotechnological Association, executive committee member of RDPAC, and alumina tutor of Management School of Fudan University. He possesses EMBA from University of Washington and Fudan University. Sean and his family are based in Shanghai. |